- 主辦 / 主持人
- 台灣臨床腫瘤醫學會
- 積分
- B類 2 分
- 分類
- 一般學術研討會 (B)
- 聯絡人
- 台灣臨床腫瘤醫學會02-2828-5502
- 活動日期
- 2021-04-24 (六) 14:00 ~ 18:00
- 地點
- 北/中/南三地視訊會議
- 說明
- Non-small-cell lung cancer (NSCLC) is believed as one of the main reasons that cause deaths from cancer worldwide. Three generations of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are now approved in the first-line setting for patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Recent randomized trials have demonstrated that 2nd and 3rd TKIs all confer significantly improved progression-free survival versus first-generation TKIs. The forum will invite Prof. Byoung Chul Cho to give the year in review of NSLCL key data and have a deep and broader discussion. \ Moreover, how to translate the RCTs into the real world to benefit Taiwan NSCLC patients is a critical issue. Therefore, how to implement the treatment strategy based on the evidences and the real world experiences sharing in various NSCLC populations, including the population on sequence treatment, BM and squamous populations will be provided in the symposium.
摘要檔案: 講師abstract.docx
2021-04-24 北/中/南三地視訊會議
| 時間 | 主題 | |
|---|---|---|
| 沒有資料 | ||